• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

造血发育异常中单个成红细胞的血红蛋白含量:成熟后期存在明显异质性。

Hemoglobin content of individual erythroblasts in hematopoietic dysplasia: marked heterogeneity at late stages of maturation.

作者信息

Coulombel L, Tchernia G, Mielot F, Mohandas N

出版信息

Exp Hematol. 1984 Aug;12(7):587-93.

PMID:6745333
Abstract

Defective hemoglobin synthesis and gross morphologic abnormalities of erythroblasts are striking features of hematopoietic dysplasia. In order to define the effects of defective hemoglobin synthesis on hemoglobin content of erythroblasts at each stage of maturation, we measured the hemoglobin content and concentration of individual erythroblasts at various stages of maturation in the bone marrow by scanning microspectrophotometry. In contrast to normal erythroblasts, those from hematopoietic dysplasia had decreased hemoglobin content and decreased hemoglobin concentration at late stages of maturation. This observation, together with the observed near-normal hemoglobin content and concentration of circulating red cells in this disorder, suggests that polychromatophilic erythroblasts with decreased hemoglobin content fail to complete normal maturation. The abnormalities in hemoglobin content observed in vivo in hematopoietic dysplasia could be reproduced in the in vitro cultures of erythroid progenitors of bone marrow cells from the patients.

摘要

血红蛋白合成缺陷和幼红细胞的明显形态学异常是造血发育异常的显著特征。为了确定血红蛋白合成缺陷对各成熟阶段幼红细胞血红蛋白含量的影响,我们通过扫描显微分光光度法测量了骨髓中不同成熟阶段单个幼红细胞的血红蛋白含量和浓度。与正常幼红细胞相比,造血发育异常患者的幼红细胞在成熟后期血红蛋白含量降低,血红蛋白浓度也降低。这一观察结果,连同该疾病中循环红细胞血红蛋白含量和浓度接近正常的现象,表明血红蛋白含量降低的嗜多色性幼红细胞无法完成正常成熟。造血发育异常患者体内观察到的血红蛋白含量异常在来自患者的骨髓细胞红系祖细胞的体外培养中能够重现。

相似文献

1
Hemoglobin content of individual erythroblasts in hematopoietic dysplasia: marked heterogeneity at late stages of maturation.造血发育异常中单个成红细胞的血红蛋白含量:成熟后期存在明显异质性。
Exp Hematol. 1984 Aug;12(7):587-93.
2
Beta-thalassemia and sickle cell disease in culture of early erythroid precursors: hemoglobin synthesis and ultrastructural study.早期红系前体细胞培养中的β地中海贫血和镰状细胞病:血红蛋白合成及超微结构研究
Blood Cells. 1981;7(1):179-200.
3
Peripheral blood erythroid progenitors from patients with sickle cell anemia: HPLC separation of hemoglobins and the effect of a HbF switching factor.镰状细胞贫血患者的外周血红细胞祖细胞:血红蛋白的高效液相色谱分离及HbF转换因子的作用
Prog Clin Biol Res. 1985;191:397-410.
4
In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.重组人促红细胞生成素对慢性肾衰竭患者骨髓造血的体内效应。
Eur J Med Res. 1998 Dec 16;3(12):564-70.
5
Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells.镰状细胞病中的人类CD34(+)和CD34(+)CD38(-)造血祖细胞在表型和功能上与正常细胞不同,提示存在产生F细胞的不同亚群。
Exp Hematol. 2004 May;32(5):483-93. doi: 10.1016/j.exphem.2004.02.003.
6
Physician Education: Myelodysplastic Syndrome.医师教育:骨髓增生异常综合征
Oncologist. 1996;1(4):284-287.
7
Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis.正常和加速红细胞生成过程中环氧化酶表达与活性的调节
Exp Hematol. 2004 Oct;32(10):925-34. doi: 10.1016/j.exphem.2004.07.010.
8
Erythroblasts derived in vitro from embryonic stem cells in the presence of erythropoietin do not express the TER-119 antigen.在促红细胞生成素存在的情况下,由胚胎干细胞体外诱导产生的成红细胞不表达TER-119抗原。
Exp Hematol. 2004 Jul;32(7):607-13. doi: 10.1016/j.exphem.2004.04.007.
9
Human marrow erythropoiesis in culture: III. Ultrastructural and cytochemical studies of cellular interactions.培养中的人骨髓红细胞生成:III. 细胞相互作用的超微结构和细胞化学研究
Exp Hematol. 1978 Jan;6(1):78-90.
10
In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders.
Semin Hematol. 1997 Jan;34(1):64-9.